Session Information
-
WCLC 2022
2022 World Conference on Lung Cancer
Conference Program for 2022 the World Conference on Lung Cancer
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2137
All times listed are in Vienna, Austria Time, CEST (UTC+2:00)
PL - Plenary
IBS - Interactive Breakfast Session (in-person attendees only)
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
P - Posters
EP - ePosters
WS - Workshops
LA – Lectureship Awards
IS - Industry Symposium
August 5 Fri
Aug 5 Saturday
August 6 Sat
Aug 6 Sunday
August 7 Sun
Aug 7 Monday
August 8 Mon
Aug 8 Tuesday
August 9 Tue
Aug 9
-
+
EP02.04 - Early Stage Non-small Cell Lung Cancer - Systemic Therapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Early Stage Non-small Cell Lung Cancer - Systemic Therapy
-
+
EP02.04-005 - Phase II NAUTIKA1 Study of Targeted Therapies in Stage II-III NSCLC: Preliminary Data of Neoadjuvant Alectinib for ALK+ NSCLC
Presenter: JAY M LEE- Abstract
Loading...
-
+
EP08.01 - Metastatic Non-small Cell Lung Cancer - Immunotherapy
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
-
+
EP08.01-027 - Durvalumab (D) ± Tremelimumab (T) + Chemotherapy (CT) in 1L Metastatic NSCLC: Outcomes by Tumour PD-L1 Expression in POSEIDON
Presenter: Edward B. Garon- Abstract
Loading...
-
+
EP08.02 - Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- 09:45 - 18:00
- 8/07/2022
- Location: Exhibit Hall - Hall B
- Not for CME Credit
- Type: E-Poster
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
-
+
EP08.02-041 - NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
Presenter: Alexander Drilon- Abstract
Loading... -
+
EP08.02-111 - RMC-4630, a SHP2 Inhibitor, in Combination with Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
Presenter: Melissa L Johnson- Abstract
Loading...
-
+
OA12 - Novel and Combination Strategies for SCLC
- 16:00 - 17:00
- 8/08/2022
- Location: Hall C8
- Not for CME Credit
- Type: Oral
- Track: Small Cell Lung Cancer and Neuro-Endocrine Tumors
- Moderators:Alessandra Curioni-Fontecedro, Kostas Syrigos
-
+
OA12.05 - Phase 1 Updated Exploration and First Expansion Data for DLL3-targeted T-cell Engager Tarlatamab in Small Cell Lung Cancer
16:22 - 16:32 | Presenter: Hossein Borghaei
- Abstract
Loading...
-
+
OA15 - Patient Selection in Advanced NSCLC Immunotherapy
- 14:30 - 15:30
- 8/09/2022
- Location: Hall C7
- Not for CME Credit
- Type: Oral
- Track: Metastatic Non-small Cell Lung Cancer - Immunotherapy
- Moderators:Pilar Garrido, António Araújo
-
+
OA15.04 - Association Between KRAS/STK11/KEAP1 Mutations and Outcomes in POSEIDON: Durvalumab ± Tremelimumab + Chemotherapy in mNSCLC
14:42 - 14:52 | Presenter: Solange Peters
- Abstract
Loading...
